1 |
T.A. Luger. Neuromediators--a crucial component of the skin immune system. J Dermatol Sci. 2002;30(2):pp.87-93.
DOI
|
2 |
M. Maccarrone, M. Di Rienzo, N. Battista, V. Gasperi, P. Guerrieri, A. Rossi, A. Finazzi-Agro. The Endocannabinoid System in Human Keratinocytes: Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem. 2003;278(36):pp.33896-903.
DOI
|
3 |
M. Karsak, E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino. Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science. 2007;316(5830):pp.1494-97.
DOI
|
4 |
M.L. Casanova, C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, J.W. Huffman, J.L. Jorcano, M. Guzman. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111(1):pp.43-50.
DOI
|
5 |
E. Gaffal, M. Cron, N. Glodde, T. Bald, R. Kuner, A. Zimmer, B. Lutz, T. Tuting. Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. J Immunol. 2013;190(10):pp.4929-36.
DOI
|
6 |
B.K. Srivastava, R. Soni, JZ. Patel, A. Joharapurkar, N. Sadhwani, S. Kshirsagar, B. Mishra. V. Takale, S. Gupta, P. Pandya, P. Kapadnis, M. Solanki, H. Patel, P. Mitra, M. R. Jain, P.R. Patel. Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett. 2009;19(9):pp.2546-50.
DOI
|
7 |
N. Dobrosi, B.I. Toth, G. Nagy, A. Dozsa, T. Geczy, L. Nagy, C.C. Zouboulis, R. Paus, L. Kovacs, T. Biro. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J. 2008;22(10):pp.3685-95.
DOI
|
8 |
J.M. Walker, A.G. Hohmann. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol. 2005;168:pp.509-54.
DOI
|
9 |
M.D. Jhaveri, D. Richardson, V. Chapman. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol. 2007;152(5):pp.624-32.
DOI
|
10 |
B.I. Toth, N. Dobrosi, A. Dajnoki, G. Czifra, A. Olah, A.G. Szollosi, I. Juhasz, K. Sugawara, R. Paus, T. Biro. Endocannabinoids Modulate Human Epidermal Keratinocyte Proliferation and Survival via the Sequential Engagement of Cannabinoid Receptor-1 and Transient Receptor Potential Vanilloid-1. J Invest Dermatol. 2011;131(5):pp.1095-104.
DOI
|
11 |
K.F. Toth, D. Adam, T. Biro, A. Olah. Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. Molecules. 2019;24(5):pp.918.
DOI
|
12 |
H.Y. Lee. Improvement of skin barrier dysfunction by Scutellaria baicalensis GEOGI extracts through lactic acid fermentation. J Cosmet Dermatol. 2019;18(1):pp.183-91.
DOI
|
13 |
W. Peng, N. Novak. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):pp.566-74.
DOI
|
14 |
K. Kabashima. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013:70(1):pp.3-11.
DOI
|
15 |
P.M. Elias, L.C. Wood, K.R. Feingold. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat. 1999:10(3);pp.119-26.
DOI
|
16 |
A.R. Jung, S.H. Ahn, I.S. Park, S.Y. Park, S.I. Jeong, J.H. Cheon, K. Kim. Douchi (fermented Glycine max Merr.) alleviates atopic dermatitis-like skin lesions in NC/Nga mice by regulation of PKC and IL-4. BMC Complement Altern Med. 2016;16:Article No.416.
|
17 |
S. Li, Z.Q. Zhang, L.J. Wu, X.G. Zhang, Y.D. Li, Y.Y. Wang. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007;1(1):pp.51-60.
DOI
|
18 |
R.A. Muluye, Y. Bian, P.N. Alemu. Anti-inflammatory and Antimicrobial Effects of Heat-Clearing Chinese Herbs: A Current Review. J Tradit Complement Med. 2014;4(2):pp.93-98.
DOI
|
19 |
P.S. Qinghu He, Yanhong Zhang. TCM Case Studies: External Medicine. 1st edition, Beijing, PEOPLE'S MEDICAL PUBLISHING HOUSE, 2014.
|
20 |
H.Y. Cha, S.H. Ahn, J.H. Cheon, I.S. Park, J.T. Kim, K. Kim. Hataedock Treatment Has Preventive Therapeutic Effects in Atopic Dermatitis-Induced NC/Nga Mice under High-Fat Diet Conditions. Evid Based Complement Alternat Med. 2016;2016:1739760.
|
21 |
H.Y. Kim, S.H. Ahn, I.J. Yang, K. Kim. Effect of Skin Lipid Barrier Formation on Hataedock Treatment with Douchi. J Korean Med. 2017;38(2):pp.41-52.
DOI
|
22 |
J.H. Song, S.H. Ahn, J.H. Cheon, S.Y. Park, H.H. Kim, K. Kim. Effects of Hataedock with Douchi on 2,4-dinitrofluorobenzene-induced Atopic Dermatitislike Skin Lesion in NC/Nga Mice. J Physiol & Pathol Korean Med. 2016;30(2):pp.109-15.
DOI
|
23 |
J.M. McPartland, G.W. Guy, V. Di Marzo. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PloS one. 2014;9(3):e89566.
DOI
|
24 |
V. Di Marzo. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):pp.623-39.
DOI
|
25 |
L.K. Miller, L.A. Devi. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev. 2011;63(3):pp.461-70.
DOI
|
26 |
G. Imokawa, A. Abe, K. Jin, Y. Higaki, M. Kawashima, A. Hidano. Decreased Level of Ceramides in Stratum Corneum of Atopic Dermatitis: An Etiologic Factor in Atopic Dry Skin?. J Invest Dermatol. 1991;96(4):pp.523-6.
DOI
|
27 |
J. Manzanares, M. Julian, A. Carrascosa. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):pp.239-57.
DOI
|
28 |
P. Pacher, S. Batkai, G. Kunos. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3);pp.389-462.
DOI
|
29 |
L. Thors, J.J. Burston, B.J. Alter, M.K. Mckinney, B.F. Cravatt, R.A. Ross, R.G. Pertwee, R.W. Gereau, J.L. Wiley, C.J. Fowler. Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. Br J Pharmacol. 2010;160(3):pp.549-60.
DOI
|
30 |
A. Dizamatova, K. Zhumanova, G.E. Zhusupova, A.I. Zhussupova, R. Srivedavyasasri, M.A. Ibrahim, S.A. Ross. A New Prenylated Isoflavonoid From Limonium leptophyllum. Nat Prod Commun. 2019;14(5):1934578X19844137.
|
31 |
K. Natsuga. Epidermal barriers. Cold Spring Harb Perspect Med. 2014;4(4):a018218.
DOI
|
32 |
C. Blanpain, E. Fuchs. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10(3):pp.207-17.
DOI
|
33 |
J.K. Kim, J.H. Lee, I.H. Bae, D.B. Seo, S.J. Lee. Beneficial Effect of a Collagen Peptide Supplement on the Epidermal Skin Barrier. Korean J Food Sci Tech. 2011;43(4):pp.458-63.
DOI
|
34 |
Kim BB, Kim JR, Kim JH, Kim YA, Park JS, Yeom MH, Lee HJ, Lee KW, Kang NJ. 7, 3', 4'-Trihydroxyisoflavone ameliorates the development of Dermatophagoides farinae-induced Atopic Dermatitis in NC/Nga Mice. Evid Based Complement Alternat Med. 2013;2013:636597
|
35 |
Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol. 2006;126:1200-02.
DOI
|
36 |
C.N. Palmer, A.D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S.P. Lee, D.R. Goudie, A. Sandilands, L.E. Campbell, F.J. Smith, G.M. O'Regan, R.M. Watson, J.E. Cecil, S.J. Bale, J.G. Compton, J.J. DiGiovanna, P. Fleckman, S. Lewis-Jones, G. Arseculeratne, A. Sergeant, C.S. Munro, B.E. Houate, K. McElreavey, L.B. Halkjaer, H. Bisgaard, S. Mukhopadhyay, W.H. McLean. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441-6.
DOI
|
37 |
M. Salzet. Invertebrate molecular neuroimmune processes. Brain Res Rev, 2000;34(1):pp.69-79.
DOI
|
38 |
O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40:965-72.
DOI
|
39 |
Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010;125(1):16-29.
DOI
|
40 |
P. Kupczyk, A. Reich, J.C. Szepietowski. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol. 2009;18(8):pp.669-79.
DOI
|
41 |
H. Yang, J. Zhou, C. Lehmann. GPR55 - a putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27(3):pp.297-302.
DOI
|
42 |
G. Nam, S.K. Jeong, B.M. Park, S.H. Lee, H.J. Kim, S.P. Hong, B. Kim, B.W. Kim. Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Ann Dermatol, 2016;28(1):pp.22-9.
DOI
|
43 |
H.J. Kim, B. Kim, B.M. Park, J.E. Jeon, S.H. Lee, S. Mann, S.K. Ahn, S.P. Hong, S.K. Jeong. Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model. Int J Dermatol. 2015;54(10):pp.401-8.
|
44 |
T. Haruna, M. Soga, Y. Morioka, K. Imura, Y. Furue, M. Yamamoto, J. Hayakawa, M. Deguchi, A. Arimura, K. Yasui. The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice. Pharmacology. 2017;99(5-6):pp.259-67.
DOI
|
45 |
G. Cantarella, M. Scollo, L. Lempereur, G. Saccani-Jotti, F. Basile, R. Bernardini. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol. 2011;82(4):pp.380-8.
DOI
|
46 |
Q. Tan, H. Yang, E. Liu, H. Wang. P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17. Mol Med Rep. 2017;16(6):pp.8863-67.
DOI
|
47 |
J.P. Thiery, J.P. Sleeman. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):pp.131-42.
DOI
|
48 |
P.F. Cheung, C.K. Wong, A.W Ho, S. Hu, D.P. Chen, C.W. Lam. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22(6):pp.453-67.
DOI
|
49 |
S. Arbabi, R.V. Maier. Mitogen-activated protein kinases. Crit Care Med. 2002;30(1) Suppl:pp.s74-9.
DOI
|